HAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE:CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Tuesday, April 15, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T 401. The reverse stock split at a ratio ranges between 1:10 and 1:20 was authorized by the Company's Board of Directors (the "Board") through unanimous written consent on October 22, 2024 and adopted by

HAIKOU, China, Dec. 18, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced successful completion of all redemptions under its Convertible Promissory Note agreement (the "Convertible Promissory Note") with Streeterville Capital, LLC as of December 11, 2024. This marks a significant step in strengthening the company's financial position and reflects its commitment to sound fiscal management. The Convertible Promissory Note was originally issued on November 17, 2021, with a principal amount of $5,250,000. Following a

HAIKOU, China, Dec. 13, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") under which the Company may offer and sell from time to time shares of common stock, par value $0.001 per share (the "Common Stock"), with an aggregate offering price of up to $600,000 (the "Financing"). The shares will be offered pursuant to a certain Securities Purchase Agreement (the "SPA") the Company entered into with certain investor (the "Investor") on December 12, 2024. Pursuant to the SPA, the Investor agrees t

3 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)

4 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)

3 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)

8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

HAIKOU, China, Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the Acquisition of Dry Eye Disease Therapeutic Device Project. This device has a patentEpidemiological research shows that the incidence rate of DED is about 25% to 30%, and the incidence rate of people over 65-year-old is 75% in ChinaAccording to the Research Report on the Market Status of the Global Dry Eye Disease Drug Industry in 2022(1), the market size of DED drugs in China in 2021 was approximately RMB3.85 billion (approximately US$0.5

SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)

SC 13G/A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)

SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)